학술논문
The value of disease-free survival (DFS) and osimertinib in adjuvant non-small-cell lung cancer (NSCLC): an international Delphi consensus report
Document Type
Article
Author
Source
In ESMO Open October 2022 7(5)
Subject
Language
ISSN
2059-7029